GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

The conversation around Semaglutide, known widely by brand names like Ozempic and Wegovy, has undeniably captured global ...

Head of the Metabolic Neuroscience Laboratory, investigates the brain ‘goo’ behind obesity and Type-2 diabetes - and how we ...

Fifty years of outstanding neuroscience research studies have revealed many secrets of how drugs of abuse affect and change ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

The European Union's medicines regulator on Friday granted a conditional authorisation for Madrigal Pharmaceuticals' drug for ...

In the context of new anti-obesity medications, the American College of Cardiology has issued a Scientific Statement updating ...

A federal judge in Texas has upheld the FDA’s decision to remove GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, from its drug shortage list, rejecting a bid by compounding pharmacies to ...

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, ...